Recap - Shares of HEB furtively peaked on Monday following an announcement that Ampligen’s advisory committee meeting date had been set, but shares were unsuccessful in maintaining … Continue Reading
Read nowInterviews - Ventrus Biosciences (NASDAQ:VTUS) believes it has hit the “trifecta of anal fissure endpoints” with its lead candidate VEN-307. In a 465 patient Phase III trial, CEO … Continue Reading
Read nowLong Ideas - By Jake King Merge Healthcare Inc. (NASDAQ:MRGE) could be seeing the first round of corporate bids next week, according to dealReporter. Offers to buy the company, … Continue Reading
Read nowLong Ideas - Exelixis (NASDAQ:EXEL) Thursday is retracing some of its losses from the beginning of the week and is up 10% from yesterday’s close, to $5.00, due … Continue Reading
Read nowMost Popular - Peregrine Pharmaceuticals (NASDAQ:PPHM) announced more bad news Thursday, after receiving a default notice from lender, Oxford Finance, on Monday. The default on the loan was … Continue Reading
Read nowLong Ideas - On Tuesday, Vertex Pharmaceuticals (NASDAQ:VRTX) announced that while it would be advancing its developmental Hepatitis C (HCV) treatment, ALS-2200, into Phase II testing, ALS-2158 didn’t … Continue Reading
Read nowLong Ideas - Wednesday morning, Catalyst Pharmaceutical Partners (NASDAQ:CPRX) announced that its previous guidance for top-line trial data at the end of September would be delayed until November. … Continue Reading
Read now